Organisation paid for research Program year 2025 Source: CMS Open Payments

US Oncology Research, Inc.

Neither a doctor nor a teaching hospital

Research payments

$1,245,580

194 payments

Through program year 2025, US Oncology Research, Inc. is reported as receiving $1,245,580 in research payments, across 194 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$117,954	1
2022	Research	$168,214	1
2020	Research	$237,585	62
2019	Research	$721,827	130

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $286,168 2 payments
F. Hoffmann-La Roche AG $255,473 43 payments
Genentech, Inc. $253,117 41 payments
Celgene Corporation $244,192 17 payments
Pharmacyclics LLC, An AbbVie Company $206,630 91 payments

Studies the money was for Research payments · program years 2019–2025

PH II Placebo Controlled of Mtig7192a and Atezo in Nsclc $253,117 41 payments
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) $244,192 17 payments
1L Nsclc DX All Comer Non Squamous $215,223 31 payments
Pilot clinical trial of treatment with bortezomib to inhibit homologous recombination HR followed by pembrolizumab and cisplatin in patients with chemotherapy-pretreated metastatic triple negative breast cancer $168,214 1 payment
Pcyc-1141-Ca $148,531 64 payments
STUDY NAME#Pilot clinical trial of treatment with bortezomib to inhibit homologous recombination HR followed by pembrolizumab and cisplatin in patients with chemotherapy-pretreated metastatic triple negative breast cancer $117,954 1 payment
Pcyc-1141-Ca $58,099 27 payments
1L Nsclc DX All Comer Squamous $40,250 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.